

European adult smokers' perceptions of the harmfulness of e-cigarettes relative to combustible cigarettes: Findings from the France and EUREST-PLUS ITC Surveys

Geoffrey T. Fong^{1,2}, Pete Driezen¹, Anne C.K. Quah¹, Thomas K. Agar¹, Raphael Andler³, Pierre Arwidson³, Antoine Deutsch⁴, Ute Mons⁵, Constantine I. Vardavas⁶, Krzysztof Przewozniak⁷, Witold Zatonski⁷, Antigona Trofor⁸, Tibor Demjén⁹, Esteve Fernandez¹⁰, Marcela Fu¹⁰, Shannon Gravely¹

¹University of Waterloo, Ontario, Canada, ²Ontario Institute for Cancer Research, Ontario, Canada, ³Santé publique France, France, ⁴Institut National du Cancer, France, ⁵University of Cologne, Germany, ⁶University of Crete, Greece, ⁷Health Promotion Foundation, Poland, ⁸University of Medicine and Pharmacy 'Grigore T. Popa' Iasi, Romania, ⁹Smoking or Health Hungarian Foundation, Hungary, ¹⁰Catalan Institute of Oncology, Spain



Presenter's disclosures



- Paid expert witness or consultant for governments defending their country's policies or regulations in litigation: Australia (plain packaging, WTO); Uruguay (labeling policies, bilateral investment treaty)
- Member, Scientific Advisory Board on Vaping Products, Health Canada (2017-2020)
- Member of the Expert Group for Article 9 (Regulation of the contents of tobacco products) and Article 10 (Regulation of tobacco product disclosures) of the WHO FCTC (2019)
- No funding or support from companies that manufacture tobacco or nicotine products.
- No funding from pharmaceutical companies

Background



- Smoked tobacco is the most dangerous form of tobacco consumption.
- Smoking cessation substantially reduces the risk for many adverse health effects.
- Most smokers want to quit smoking, and approved medical therapies significantly increase the changes of quitting (although still low % of success), but many smokers are unable to do so.
- The nicotine product landscape has diversified in recent years to include a variety of non-combustible products, notably e-cigarettes (ECs) and heated tobacco products (HTPs).

Harmfulness of ECs and importance of beliefs about their harmfulness



- Many studies have shown that harmfulness beliefs of ECs (and other tobacco and nicotine products) are associated both concurrently and prospectively with the likelihood of product use.
- A key determinant of smokers using ECs to quit is whether they perceive ECs to be less harmful than cigarettes.

Cochrane Review Update (Nov 17, 2022) ECs for smoking cessation review





Cochrane Database of Systematic Reviews

Electronic cigarettes for smoking cessation (Review)

Hartmann-Boyce J, Lindson N, Butler AR, McRobbie H, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Fanshawe TR, Hajek P

Evaluated the effect of using e-cigarettes to help people who smoke achieve long-term smoking abstinence

- Included 78 studies, representing 22,052 participants, 40 RCTs
- Conclusions:
 - High-certainty evidence that ECs with nicotine increase quit rates compared to NRT
 - Moderate-certainty evidence that ECs with nicotine increase quit rates compared to ECs without nicotine.
 - Evidence comparing nicotine EC with usual care/no treatment also suggests benefit, but is less certain.

Changing perceptions of harmfulness of ECs in the US: prior to EVALI





In the United States: significant changes in perceptions from 2012 to 2017:

- Less harmful: 51% to 34%
- About the same: 47% to 56%
- More harmful: 3% to 10%

Perceived Harm of Electronic Cigarettes Relative to Combustible Cigarettes in the Health Information National Trends Surveys

Huang et al., JAMA Netw Open, 2019. Changing perceptions of harm of e-cigarette vs cigarette use among US adults (current, former, non-smokers).

Perception of harmfulness of e-cigarettes among smokers in 6 EU countries (EUREST Plus/ITC): 2016 and 2018





Gravely et al., Eur J Public Health, 2020. European adult smokers' perceptions of the harmfulness of e-cigarettes relative to combustible cigarettes: cohort findings from the 2016 and 2018 EUREST-PLUS ITC Europe Surveys

Changing perceptions associated with EVALI

2019: Pre-EVALI (Summer) 2020: EVALI

- Less harmful: 34% to 24%
- More harmful: 12% to 28%



Trends in harm perceptions of E-cigarettes versus cigarettes, HINTS, U.S. adults aged ≥18 years. (A) Annual 2018–2020. (B) Monthly, 2020.

Bandi et al. Am J Prev Med, 2022. Relative harm perceptions of e-cigarettes versus cigarettes, U.S. adults, 2018–2020.



ITC France Survey

- ITC 2019 France Survey (Oct 31 to Dec 17, 2019)
- Computer Assisted Telephone Interview (CATI)
- N = 2,212 (1,679 Smokers + 533 Non-Smokers)
- Current study: examined perceptions of harmfulness of ECs compared to cigarettes in France and six European (EU) countries

Santé

publique

RÉPUBLIQUE FRANÇAISE

Liberté Égalité Fraternii / INSTITUT

- Cross-sectional analyses: Data were drawn from:
 - 2019 ITC France Survey (n=1573)
 - 2018 EUREST-PLUS Surveys conducted in 6 EU countries Germany, Greece, Hungary, Poland, Romania, and Spain (n=4023)

Methods

 Current adult (≥18 years) cigarette smokers (≥monthly) who were aware of ECs were included.

Santé

publique

RÉPUBLIQUE FRANÇAISE

Liberté Égalité Fraternii / INSTITUT NATIONAL

- Compared to smoking ordinary cigarettes, how harmful do you think it is to use e-cigarettes?
 - "less harmful"; "equally harmful"; "more harmful"; "don't know"
- How do you think it would affect the health of a smoker if they quit smoking cigarettes and switched completely to e-cigarettes long-term: "improve health"; "no effect"; "make health worse"; "don't know"
- Multinomial weighted regression
 - Adjusted for: sex, age, smoking frequency (daily vs. non-daily), current EC use (yes vs. no)

Sample Characteristics of Smokers in the 7 Countries



	France	Germany	Greece	Hungary	Poland	Romania	Spain
Sex							
Female	47.4	52.2	45.2	49.5	54.2	45.1	45.6
Age Group							
18-24	33.8	6.6	5.0	6.4	8.6	9.8	9.8
25-39	20.4	26.6	24.7	27.4	31.4	26.6	28.2
40-54	21.4	32.6	40.0	35.7	27.5	35.8	37.6
55+	24.5	34.2	30.3	30.5	32.4	27.8	24.4
Daily smoking	84.8	90.0	98.2	97.6	96.0	97.9	96.7
Aware of ECs	93.7	72.1	80.3	70.5	61.3	61.0	86.8

Relative harmfulness beliefs: ECs compared to cigs



• The belief that ECs are less harmful than cigarettes was highest in France (44%), followed by Greece and Hungary (35%), Spain (30%), Germany (33%), Poland (29%) and Romania (20%)

% believing that ECs are equally or more harmful



The majority of smokers in 6 of the 7 EU countries believe that ECs are at least as harmful as cigarettes, being highest in Germany and Poland (62%) and lowest in France, but still high (42%)

% believing ECs are less harmful in 23 ITC countries: 15 high-income and 8 low/middle-income





Results





Nearly half of smokers believe that there would be no effect (except France at 36%); 1/2 to 2/3 believe that there would be no effect or that switching completely to vaping would actually worsen health (except France: 36%)
Belief that completely switching from cigs to ECs improves health: highest in France (36%) lowest in Romania (16%)

Conclusions



- Although the long-term risks of ECs are not known, multiple reviews (e.g., US NASEM, PHE/OHID, Cochrane) have concluded that ECs expose users to fewer toxicants than cigarette smoking.
- The majority of smokers in 6 of the 7 EU countries, except for France, believed that ECs are as harmful as or more harmful than cigarettes.
- About half of smokers in 6 countries believe that completely switching from cigarettes to ECs would have no effect on health; 6-18% believe that switching completely from smoking to vaping would worsen their health. (12% in France)
- Many studies have shown a significant relationship between perceptions of harm and use of ECs. Thus, smokers who believe that ECs are as harmful or more harmful than cigarettes will be less likely to try to use or sustain use of ECs to quit smoking.
- Communication affects harmfulness perceptions (e.g., EVALI)

Funding Acknowledgements



- The 2019 ITC France (FRA) Survey was supported by grants from Santé publique France, Institut national du cancer (INCa), andthe Canadian Institutes of Health Research (Foundation Grant FDN-148477).
- The EUREST-PLUS Project (including the ITC Six European Countries Cohort Study) was supported by European Commission H2020 Health (681109) and the University of Waterloo Office of Research (Fong).
- The preparation of this presentation was supported by the Canadian Institutes of Health Research Foundation Grant (FDN-148477).
- Additional support to GTF is provided by the Ontario Institute for Cancer Research, Ontario, Canada.

Major Support for the ITC Project





US National Cancer Institute P01 CA200512



Canadian Institutes of Health Research FDN-148477



Ontario Institute for Cancer Research Senior Investigator Award (2007-2022)

ITC Project Research Organizations							
UIC University of Illinois at Chicago	WATERLOO						
Income Income<	an ar an						
	iet						

ITC Project Research Support								
UNIVERSITY OF MALAYA	8 Constitution							
ロンシュロ20 シュニューロー シューロー ショーロー シューロー ショーロー ショーロー シューロー ショーロー ショーロ	dkfz.							